These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21838594)

  • 1. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Chou B; Halladay JS; Olivero AG; Rudewicz PJ; Tian Q; Wong S; Zhang X
    Xenobiotica; 2011 Dec; 41(12):1088-99. PubMed ID: 21838594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
    Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
    Choo EF; Driscoll JP; Feng J; Liederer B; Plise E; Randolph N; Shin Y; Wong S; Ran Y
    Xenobiotica; 2009 Sep; 39(9):700-9. PubMed ID: 19552528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
    Wong H; Gould SE; Budha N; Darbonne WC; Kadel EE; La H; Alicke B; Halladay JS; Erickson R; Portera C; Tolcher AW; Infante JR; Mamounas M; Flygare JA; Hop CE; Fairbrother WJ
    Drug Metab Dispos; 2013 Dec; 41(12):2104-13. PubMed ID: 24041744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
    Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
    Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
    O'Brien C; Wallin JJ; Sampath D; GuhaThakurta D; Savage H; Punnoose EA; Guan J; Berry L; Prior WW; Amler LC; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2010 Jul; 16(14):3670-83. PubMed ID: 20453058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
    Liu L; Halladay JS; Shin Y; Wong S; Coraggio M; La H; Baumgardner M; Le H; Gopaul S; Boggs J; Kuebler P; Davis JC; Liao XC; Lubach JW; Deese A; Sowell CG; Currie KS; Young WB; Khojasteh SC; Hop CE; Wong H
    Drug Metab Dispos; 2011 Oct; 39(10):1840-9. PubMed ID: 21742900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process.
    Choo EF; Alicke B; Boggs J; Dinkel V; Gould S; Grina J; West K; Menghrajani K; Ran Y; Rudolph J; Wenglowsky S
    Xenobiotica; 2011 Dec; 41(12):1076-87. PubMed ID: 21864203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
    Choo EF; Ng CM; Berry L; Belvin M; Lewin-Koh N; Merchant M; Salphati L
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):133-43. PubMed ID: 23053270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
    J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Lee LB; Pang J; Plise EG; Zhang X
    Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.